drugset
drugset / Trial / NCT03483506

This Study in Healthy Men Tests How the Body Takes up BI 1467335

NCT03483506 ↗

Phase 1 Completed 12 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this trial is to investigate the absolute bioavailability of BI 1467335 with an intravenous microdose formulation containing labelled \[C-14\] BI 1467335 and an unlabelled oral tablet formulation of BI 1467335 in healthy male subjects. The secondary objective is the evaluation of additional pharmacokinetic parameters following the two treatments.

Timeline

Start
2018-04-10
Primary completion
2018-06-27
Completion
2018-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1467335 Unknown — Oral

Indications

No indication recorded.